Profile data is unavailable for this security.
About the company
Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
- Revenue in USD (TTM)0.00
- Net income in USD-15.84m
- Incorporated2019
- Employees5.00
- LocationGalecto IncOle Maaloes Vej 3COPENHAGEN OE 2200DenmarkDNK
- Phone+1 3 026587581
- Fax+1 3 026555049
- Websitehttps://galecto.com/
More ▼
Mergers & acquisitions
| Acquired company | GLTO:NAQ since announced | Transaction value |
|---|---|---|
| Damora Therapeutics Inc | 495.05% | 1.31m |
Data delayed at least 15 minutes, as of Mar 02 2026 16:59 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oruka Therapeutics Inc | 0.00 | -101.63m | 1.67bn | 28.00 | -- | 3.44 | -- | -- | -2.36 | -2.36 | 0.00 | 10.06 | 0.00 | -- | -- | 0.00 | -22.01 | -32.95 | -22.98 | -34.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1,468.16 | -- | 116.21 | -- |
| Amylyx Pharmaceuticals Inc | 0.00 | -149.28m | 1.67bn | 123.00 | -- | 5.02 | -- | -- | -1.80 | -1.80 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.67 | -51.56 | -55.94 | -60.70 | -- | -- | -- | -118.26 | -- | -- | 0.00 | -- | -77.06 | 127.75 | -712.42 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -105.64m | 1.68bn | 60.00 | -- | 6.43 | -- | -- | -11.08 | -11.08 | 0.00 | 9.02 | 0.00 | -- | -- | 0.00 | -77.05 | -49.22 | -84.35 | -54.31 | -- | -- | -- | -4,359.44 | -- | -- | 0.00 | -- | -- | -- | -11.19 | -- | -32.77 | -- |
| Palvella Therapeutics Inc | 0.00 | -35.07m | 1.71bn | 14.00 | -- | 38.70 | -- | -- | -3.83 | -3.83 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -80.19 | -31.18 | -96.21 | -43.15 | -- | -- | -- | -122.22 | -- | -3.05 | 0.2929 | -- | -100.00 | -- | 28.97 | -- | -- | -- |
| Definium Therapeutics Inc | 0.00 | -183.79m | 1.74bn | 105.00 | -- | 5.19 | -- | -- | -2.06 | -2.06 | 0.00 | 3.36 | 0.00 | -- | -- | 0.00 | -49.52 | -52.67 | -57.73 | -60.64 | -- | -- | -- | -- | -- | -- | 0.1088 | -- | -- | -- | -69.12 | -- | -- | -- |
| Zymeworks Inc | 134.48m | -63.43m | 1.74bn | 263.00 | -- | 5.51 | -- | 12.96 | -0.8448 | -0.8448 | 1.78 | 4.23 | 0.3041 | -- | 5.07 | 480,289.30 | -14.34 | -19.80 | -16.73 | -23.38 | -- | -- | -47.16 | -80.81 | -- | -- | 0.00 | -- | 0.3842 | 20.90 | -3.39 | -- | -26.07 | -- |
| Enliven Therapeutics Inc | 0.00 | -97.21m | 1.76bn | 65.00 | -- | 3.70 | -- | -- | -1.85 | -1.85 | 0.00 | 8.03 | 0.00 | -- | -- | 0.00 | -24.41 | -35.02 | -25.43 | -38.16 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.36 | -- | -20.66 | -- |
| Agios Pharmaceuticals Inc | 54.03m | -412.78m | 1.77bn | 539.00 | -- | 1.48 | -- | 32.78 | -7.12 | -7.12 | 0.932 | 20.41 | 0.0365 | 0.2096 | 7.36 | 100,237.50 | -27.89 | -10.70 | -29.52 | -11.34 | 88.26 | -- | -764.01 | -516.35 | 11.06 | -- | 0.00 | -- | 48.03 | -- | -161.27 | -- | -21.96 | -- |
| Tyra Biosciences Inc | 0.00 | -111.68m | 1.78bn | 60.00 | -- | 6.33 | -- | -- | -1.88 | -1.88 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -32.73 | -24.74 | -34.14 | -25.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.09 | -- | 101.48 | -- |
| Galecto Inc | 0.00 | -15.84m | 1.78bn | 5.00 | -- | 5.89 | -- | -- | -12.01 | -12.01 | 0.00 | 6.03 | 0.00 | -- | -- | 0.00 | -92.89 | -47.05 | -109.09 | -50.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 44.10 | -- | -- | -- |
| Pharvaris NV | 0.00 | -193.40m | 1.82bn | 108.00 | -- | 5.00 | -- | -- | -3.45 | -3.45 | 0.00 | 5.68 | 0.00 | -- | -- | 0.00 | -50.22 | -36.71 | -53.72 | -38.87 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -33.06 | -- | 109.04 | -- |
| Relay Therapeutics Inc | 15.36m | -276.48m | 1.83bn | 192.00 | -- | 3.15 | -- | 119.41 | -1.61 | -1.61 | 0.0895 | 3.26 | 0.0206 | -- | -- | 79,979.16 | -37.05 | -35.52 | -39.04 | -37.06 | -- | -- | -1,800.46 | -2,911.42 | -- | -- | 0.00 | -- | 53.44 | -28.58 | 18.13 | -- | -26.65 | -- |
| Semnur Pharmaceuticals Inc | 0.00 | -1.46m | 1.84bn | -- | -- | -- | -- | -- | -0.4678 | -0.4678 | 0.00 | -4.05 | 0.00 | -- | -- | -- | -5.54 | -- | -7.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -126.45 | -- | -- | -- |
| Nektar Therapeutics | 62.60m | -120.74m | 1.88bn | 61.00 | -- | 15.93 | -- | 30.07 | -7.93 | -7.93 | 4.10 | 4.33 | 0.2055 | -- | 97.13 | 1,026,230.00 | -37.21 | -35.30 | -47.69 | -39.56 | 87.26 | 75.63 | -181.08 | -323.39 | -- | -8.54 | 0.469 | -- | 9.22 | -3.00 | 56.91 | -- | -43.84 | -- |
| Olema Pharmaceuticals Inc | 0.00 | -149.96m | 1.90bn | 122.00 | -- | 5.40 | -- | -- | -1.81 | -1.81 | 0.00 | 4.48 | 0.00 | -- | -- | 0.00 | -51.48 | -31.26 | -58.78 | -33.05 | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -- | -- | -33.95 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Galecto Inc's reporting currency: US Dollar USD
16.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fairmount Funds Management LLCas of 09 Feb 2026 | 8.71m | 14.47% |
| Ikarian Capital LLCas of 31 Dec 2025 | 285.71k | 0.47% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 238.88k | 0.40% |
| Jain Global LLCas of 31 Dec 2025 | 120.57k | 0.20% |
| Point72 Asset Management LPas of 31 Dec 2025 | 109.00k | 0.18% |
| Boothbay Fund Management LLCas of 31 Dec 2025 | 95.80k | 0.16% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 74.92k | 0.12% |
| Sigma Planning Corp.as of 31 Dec 2025 | 14.50k | 0.02% |
| Geode Capital Management LLCas of 31 Dec 2025 | 11.57k | 0.02% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 11.03k | 0.02% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
